MBX Biosciences, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2022 | — | $-42.6M | — |
| FY2023 | — | $-72.5M | $30.5M |
| FY2024 | — | $257.4M | $49.4M |
| FY2025 | — | $369.2M | $75.3M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2022 | — | $-42.6M | — |
| FY2023 | — | $-72.5M | $30.5M |
| FY2024 | — | $257.4M | $49.4M |
| FY2025 | — | $369.2M | $75.3M |